Form 4: Cogent Biosciences Director Acquires Stock Options in Lieu of Cash Compensation

Director Karen Jean Ferrante acquired 3,213 stock options in Cogent Biosciences in lieu of cash compensation on April 1, 2024.

Summary

• On April 1, 2024, Karen Jean Ferrante, a director of Cogent Biosciences, Inc., acquired 3,213 stock options.
• The options were granted in lieu of cash compensation for services as a director, as per the Issuer's non-employee director compensation plan.
• The exercise price of the options is $6.90.
• The options are exercisable from April 1, 2024, and expire on April 1, 2034.
• The number of options granted was determined by dividing the cash compensation otherwise payable for the quarter by the Black-Scholes value of a single option on the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, and there's no indication of positive or negative implications for the company's performance.

Positives

• The acquisition of stock options by a director demonstrates confidence in the company's future performance.
• Using stock options in lieu of cash compensation can conserve the company's cash reserves.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Directors often receive stock options as part of their compensation packages.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates